Not logged inheredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
Kuemmel, Sherko; Harper-Wynne, Catherine; Park, Yeon Hee; Franke, Fabio; de Laurentiis, Michelino; Schumacher-Wulf, Eva; Eiger, Daniel; Heeson, Sarah; Cardona, Andres; Ozyilkan, Ozgur; Morales-Vasquez, Flavia; Metcalfe, Ciara; Hafner, Marc; Restuccia, Eleonora; O'Shaughnessy, Joyce .png)
Share.png)
SaveheredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+advanced breast cancerKuemmel, Sherko; Harper-Wynne, Catherine; Park, Yeon H.; Franke, Fabio; De laurentiis, Michelino; Schumacher-Wulf, Eva; Eiger, Daniel; Heeson, Sarah; Shivhare, Mahesh; Restuccia, Eleonora; O'Shaughnessy, Joyce Share Save Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSwain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle Share Save Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trialTabernero, Josep; Hoff, Paulo M.; Shen, Lin; Ohtsu, Atsushi; Shah, Manish A.; Siddiqui, Asna; Heeson, Sarah; Kiermaier, Astrid; Macharia, Harrison; Restuccia, Eleonora; Kang, Yoon-Koo Share Save Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialGelber, Richard D.; Wang, Xin, V; Cole, Bernard F.; Cameron, David; Cardoso, Fatima; Tjan-Heijnen, Vivianne; Krop, Ian; Loi, Sherene; Salgado, Roberto; Kiermaier, Astrid; Frank, Elizabeth; Fumagalli, Debora; Caballero, Carmela; de Azambuja, Evandro; Procter, Marion; Clark, Emma; Restuccia, Eleonora; Heeson, Sarah; Bines, Jose; Loibl, Sibylle; Piccart-Gebhart, Martine Share Save Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)Swain, S. M.; Tan, A.; Gianni, L.; Kummel, S.; Dang, C.; Schneeweiss, A.; O'Shaughnessy, J.; Liu, H.; Aguila, C.; Heeson, S.; Macharia, H.; Restuccia, E.; Loibl, S. Share Save Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa studyIm, S-A.; Tan, A. R.; Mattar, A.; Colomer, R.; Stroyakovskii, D.; Nowecki, Z.; De Laurentiis, M.; Pierga, J-Y.; Jung, K. H.; Schem, C.; Aguila, C.; Crnjevic, T. Badovinac; Heeson, S.; Shivhare, M.; Alexandrou, A.; Restuccia, E.; Jackisch, C. Share Save End-of-study analysis from JACOB: A phase III study of pertuzumab (P) plus trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)Tabernero, J.; Hoff, P. M.; Shen, L.; Ohtsu, A.; Shah, M. A.; Siddiqui, A.; Heeson, S.; Wu, H.; Restuccia, E.; Kang, Y-K. Share Save Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa studyTan, Antoinette R.; Im, Seock-Ah; Mattar, Andre; Colomer, Ramon; Stroyakovskii, Daniil; Nowecki, Zbigniew; De laurentiis, Michelino; Pierga, Jean-Yves; Jung, Kyung Hae; Schem, Christian; Heeson, Sarah; Shivhare, Mahesh; Kirschbrown, Whitney P.; Restuccia, Eleonora; Crnjevic, Tanja Badovinac; Jackisch, Christian Share Save Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab (vol 28, pg 761, 2017)Swain, S. M.; Schneeweiss, A.; Gianni, L.; Gao, J. J.; Stein, A.; Waldron-Lynch, M.; Heeson, S.; Beattie, M. S.; Yoo, B.; Cortes, J.; Baselga, J. Share Save Share Save Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabSwain, S. M.; Schneeweiss, A.; Gianni, L.; Gao, J. J.; Stein, A.; Waldron-Lynch, M.; Heeson, S.; Beattie, M. S.; Yoo, B.; Cortes, J.; Baselga, J. Share Save Share Save Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabSwain, S. M.; Schneeweiss, A.; Gianni, L.; Stein, A.; McNally, V.; Heeson, S.; Portera, C.; Yoo, B.; Cortes, J. C.; Baselga, J. Share Save Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerSwain, Sandra M.; Baselga, Jose; Kim, Sung-Bae; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-Marc; Schneeweiss, Andreas; Heeson, Sarah; Clark, Emma; Ross, Graham; Benyunes, Mark C.; Cortes, Javier Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
BMC CANCER.png)
OAAI
OAAI